Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Araris Biotech AG
Headquarters: Zurich, Switzerland
Website: https://www.ararisbiotech.com...
Year Founded: 2019
Status: Private
BioCentury | Mar 17, 2025
Deals
AZ acquires cell therapy play Esobiotech, Taiho acquires ADC partner Araris: Deals Report
Plus: Roche partners with Zealand, AZ with Alteogen and more
BioCentury | Oct 5, 2023
Management Tracks
Jonsson to succeed Mason as head of Lilly Diabetes and Obesity
Plus: Grabulovski takes over as CEO of Araris and updates from IGM, Odyssey, Alpine, Nuvig, Rome, Saghmos, Nature’s Toolbox and Myricx
BioCentury | Oct 13, 2022
Management Tracks
Maag becomes CEO at Kyverna
Plus Bernstein to head R&D at Maze, and updates from Visiox, Araris, Quest and Biohaven
BioCentury | Oct 6, 2022
Regulation
Oct. 5 Quick Takes: Eiger won’t submit EUA for COVID-19 candidate
Plus Global Blood now part of Pfizer, and updates from Araris, Valitor, Connect and more
BioCentury | Apr 2, 2021
Management Tracks
O’Brien to head NPC; plus moves at Frontier, Araris, Montis and more
The National Pharmaceutical Council (NPC) hired John O’Brien, former senior adviser to the U.S. secretary of HHS, as president and CEO, effective June 1. Prior to his role at HHS,
BioCentury | Mar 6, 2021
Emerging Company Profile
Araris: universal linkers for antibody-drug conjugates
Emerging Company Profile: Swiss newco is developing peptide linkers that could improve ADC’s therapeutic window
BioCentury | Oct 24, 2020
Finance
Oct. 23 Quick Takes: RA Capital’s $461M new fund; plus venture rounds for Sirnaomics, 3D Medicines, Zhaoke, Orbus, Araris
New $461M venture fund for RA RA Capital raised $461 million for its Nexus Fund II, its second venture fund that like 2019’s $300 million Nexus I Fund will invest in private companies
BioCentury | Aug 21, 2019
Financial News
Aug. 20 Financial Quick Takes: WuXi companies report increased profits; plus Graybug, Araris and Sarepta
Items per page:
1 - 8 of 8